{
    "clinical_study": {
        "@rank": "75619", 
        "arm_group": {
            "arm_group_label": "Eculizumab", 
            "arm_group_type": "Experimental", 
            "description": "Eculizumab intravenous infusion every two weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether eculizumab long-term use is safe and\n      effective in patients with relapsing NMO."
        }, 
        "brief_title": "An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuromyelitis Optica", 
            "Neuromyelitis Optica Spectrum Disorder"
        ], 
        "condition_browse": {
            "mesh_term": "Neuromyelitis Optica"
        }, 
        "detailed_description": {
            "textblock": "This study is an open label extension study to confirm the long term safety and efficacy of\n      eculizumab in subjects with relapsing NMO who have completed the initial double-blind,\n      randomized, placebo-controlled trial ECU-NMO-301."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Patient completed the ECU-NMO-301 trial\n\n          2. Patient has given written informed consent\n\n        Key Exclusion Criteria:\n\n          1. Patients who have withdrawn from the ECU-NMO-301 trial as a result of an AE related\n             to trial drug\n\n          2. Female patients who are pregnant, breastfeeding, or intend to conceive during the\n             course of the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003144", 
            "org_study_id": "ECU-NMO-302", 
            "secondary_id": "2013-001151-12"
        }, 
        "intervention": {
            "arm_group_label": "Eculizumab", 
            "intervention_name": "eculizumab", 
            "intervention_type": "Biological", 
            "other_name": "Soliris"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Long-term safety study", 
            "Extension trial", 
            "Eculizumab", 
            "Neuromyelitis Optica Spectrum Disorder", 
            "Devic's disease", 
            "Transverse Myelitis", 
            "Optic Neuritis", 
            "Relapse", 
            "NMO-IgG", 
            "CNS Autoimmune Disorders", 
            "Demyelinating Disorders"
        ], 
        "lastchanged_date": "December 2, 2013", 
        "number_of_arms": "1", 
        "official_title": "A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)", 
        "other_outcome": {
            "description": "Change in plasma PK of eculizumab and in free C5 activity (PD marker) before and after treatment with the study drug.", 
            "measure": "Describe the pharmacokinetics (PK) and pharmacodynamics (PD) of eculizumab in patients with relapsing NMO", 
            "safety_issue": "No", 
            "time_frame": "From first dose to study completion (maximum of 4 years)."
        }, 
        "overall_contact": {
            "email": "clinicaltrials@alxn.com", 
            "last_name": "Alexion Pharmaceuticals (Sponsor)"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), change from baseline in vital signs, clinical laboratory tests, and suicide risk as assessed with Columbia-Suicide Rating Scale (C-SSRS)", 
            "measure": "Evaluate the long-term safety of eculizumab in patients with relapsing NMO.", 
            "safety_issue": "Yes", 
            "time_frame": "From first dose to study completion (maximum of 4 years)."
        }, 
        "reference": {
            "PMID": "23623397", 
            "citation": "Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013 Jun;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0. Epub 2013 Apr 26."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003144"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change from baseline in Annualized Relapsing Rate, disability, quality of life and neurologic function.", 
            "measure": "Evaluate the long-term efficacy of eculizumab in patients with relapsing NMO", 
            "safety_issue": "No", 
            "time_frame": "From first dose to study completion (maximum of 4 years)."
        }, 
        "source": "Alexion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}